Tango Therapeutics TNGX Accrued Expenses
Accrued Expenses at other companies
Other financials
Where this comes from
Reported directly by Tango Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:EmployeeRelatedLiabilitiesCurrent.
The official record: Tango Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Tango Therapeutics's accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Tango Therapeutics's accrued expenses?
- Tango Therapeutics (TNGX) reported accrued expenses of $3.24M in Q1 2026.
- How has Tango Therapeutics's accrued expenses changed year-over-year?
- Tango Therapeutics's accrued expenses increased by 1.9% year-over-year, from $3.18M to $3.24M.
- What is the long-term trend for Tango Therapeutics's accrued expenses?
- Over 5 years (2020 to 2025), Tango Therapeutics's accrued expenses has grown at a 27.8% compound annual growth rate (CAGR), from $2.65M to $9.05M.
- What does accrued expenses mean?
- Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.